Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
аАКДС-Геп В+Hib (also known as АКДС-Геп В + Hib) is an approved pentavalent combination vaccine developed by Immunopreparat (a subsidiary of Microgen). It is indicated for the active immunization of children against diphtheria, tetanus, pertussis, hepatitis B, and Haemophilus influenzae type b (Hib) infection. The vaccine is formulated as a suspension for intramuscular injection, consisting of an acellular pertussis component (which reduces reactogenicity compared to whole-cell vaccines), diphtheria and tetanus toxoids, recombinant hepatitis B surface antigen (HBsAg), and a synthetic conjugated Hib capsular polysaccharide (polyribosylribitol phosphate) component. It is adsorbed onto aluminum hydroxide as an adjuvant to enhance the protective humoral immune response against all five targeted pathogens.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on аАКДС-Геп В+Hib.